|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2009-11-5
|
|
pubmed:abstractText |
Only few predictive factors for the clinical activity of anti-epidermal growth factor receptor (EGFR) therapy are available. Mammary-derived growth inhibitor (MDGI) is a small cytosolic protein suggested to play a role in the differentiation of epithelial cells. Here, we have investigated the effect of MDGI expression on the EGFR signaling and cetuximab responsiveness of cancer cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BonoPetriP,
pubmed-author:HeikkiläPäiviP,
pubmed-author:IljinKristiinaK,
pubmed-author:IvaskaJohannaJ,
pubmed-author:JoensuuHeikkiH,
pubmed-author:KallioniemiOlliO,
pubmed-author:MattilaElinaE,
pubmed-author:NevoJonnaJ,
pubmed-author:PellinenTeijoT,
pubmed-author:SaraHenriH,
pubmed-author:WärriAnniA,
pubmed-author:YamamotoDaniel LDL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6570-81
|
|
pubmed:meshHeading |
pubmed-meshheading:19825952-Animals,
pubmed-meshheading:19825952-Antibodies, Monoclonal,
pubmed-meshheading:19825952-Breast Neoplasms,
pubmed-meshheading:19825952-Cell Line, Tumor,
pubmed-meshheading:19825952-Drug Resistance, Neoplasm,
pubmed-meshheading:19825952-Fatty Acid-Binding Proteins,
pubmed-meshheading:19825952-Female,
pubmed-meshheading:19825952-Lung Neoplasms,
pubmed-meshheading:19825952-Mice,
pubmed-meshheading:19825952-Mice, Nude,
pubmed-meshheading:19825952-RNA, Messenger,
pubmed-meshheading:19825952-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19825952-Signal Transduction,
pubmed-meshheading:19825952-Tumor Cells, Cultured,
pubmed-meshheading:19825952-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance.
|
|
pubmed:affiliation |
Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
